Quick Answer
Caris Life Sciences, Inc. reported R&D Expense of $101.58 million for fiscal year 2025.
Caris Life Sciences, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $101.58M | -10.8% |
| 2024 | $113.92M | -2.5% |
| 2023 | $116.88M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $21.62M | -21.8% | -13.7% |
| June 30, 2025 | $25.05M | +1.0% | -9.4% |
| September 30, 2024 | $27.64M | — | +11.5% |
| June 30, 2024 | $24.79M | — | — |
- Caris Life Sciences, Inc. showed a decrease of -10.8% in R&D Expense compared to the prior fiscal year.
- Over the 2023–2025 period, Caris Life Sciences, Inc.’s r&d expense has declined by 13.1% (from $116.88 million to $101.58 million).
- The most recent figure is from Caris Life Sciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: